Medical network on March 6 - the national basic medical insurance, inductrial injury insurance and maternity insurance drug catalogue (2017 edition) "(hereinafter referred to as the new catalogue of the health care) are stirring the whole pharmaceutical industry.
More imagination space is, the new adjustment of Chinese and western medicine in the catalogue of health care a total of 2535, 2009 more than 2009 version of the directory. Part of western medicine, 1297, an increase of 133 kinds, proprietary Chinese medicine section 1238, an increase of 251 kinds. , on the basis of people club department, a new version of the catalogue of health b 15% of the drug are local directory permissions, adjustable provinces supplemented after adjustment for July 31. This is the new set of "the xxix olympiad" in the catalogue of health care. ; New catalogue of health care is also the stage, put forward "to establish access to health care medicine negotiation mechanism", the first to determine the clinical value of 45 high but relatively expensive, exclusive patent drugs according to related procedure organization talks.
Next, many companies will weigh up the pros and cons carefully and coping strategies. Especially medicare drug guidance will soon pay standard come on stage, the new rules proposed medicare payment standard and hospital drugs sale price gap between allows hospital retained. Therefore, the hospital price of purchasing drug source power boost. It is not difficult to determine, soup of medicare drug market "tiebreaker" has already begun.
Local supplement for the product
With 15% of the adjusted permissions, b drug varieties, adjustable medicine, 134, 157 Chinese medicine, compared with the previous version of the additions to a certain amount of increase.
"We are very concerned about the condition of the local supplementary medical insurance directory in various provinces. It is opportunity for many companies." Guangzhou baiyun mountain pharmaceutical group co., LTD., vice general manager of chun-bo zhang said, "because of the various provinces and cities have a lot of manufacturers and varieties, the future will be very competitive. I think the new directory restrictions on antibiotic, Chinese medicine injection, enterprises will find another opportunity. Good varieties originally market is very big, relative profit space, if not into the state directory, do not rule out the possibility of into the local directory."
Keep in mind, the version into 15 above provincial health insurance directory of product is injection of 80%, and mainly is the treatment of heart head blood-vessel, injection of antibiotics and nutritional supplements. Many supplementary directory products also announced on part of the province of adjuvant or key monitoring drug product list, such as compound coenzyme, calf serum protein, blood will net injection, etc. Exclusive varieties including moxa oprah azole enteric-coated metformin hydrochloride, compound growth rate of more than 50% over the past three years. And little vasopressin for nearly three years of the market share of more than 80%.
This is why a lot of enterprise value supplement "motivation".
Chun-bo zhang, however, think: "local supplement compared with the national directory, too many variables, such as different needs around the country, local protection and so on." To card in the process, he thought, well, more depends on the competitiveness of the breed itself, namely, whether it is the sole, how much price space, high market share is not high. On strategy, exclusive varieties may not adjust on price, non-exclusive varieties to preempt the market is likely to make concessions on price. In terms of promotion, hospital varieties will strengthen the academic education of doctors and patients education, OTC varieties will increase the intensity of advertising. Non-exclusive varieties is mostly generic drug, hospital dosage is not big, and no price advantage, generic drug companies it is difficult to have the space to promote products, so enter the health impact on the enterprise is not big. And if exclusive varieties into directory will pull on sales is very large. Therefore, to not into the national health insurance directory of exclusive varieties, most enterprises will get into the supplementary directory, especially some key markets, such as a relatively developed economy, population big province. "
Health care quantity and price negotiation and promote game
Scroll through price negotiation into medical insurance directory, is another variable medicare drug market.
Involved in the national health insurance companies who told reporters: "from the learned information, finally can talk into directory estimated that only a dozen, it depends on the amount of health care costs. The core is through the bidding, price paid, according to macro-reforms combination policies to regulate the use of health care medicines."
The move leaves space for the domestic and foreign enterprises have the temptation.
Licensed novartis last year against active in China, at a 26.5% discount for a rare disease of pulmonary hypertension import prices by 80% of targeted drugs, the treatment of astrazeneca prices more than 50%, and so on. The enterprise person said: "local drug firms in the market promotion of innovative medicine, and the resources, experience, rich in such aspects as global support multinational drug companies compared with the weak. I think, the original drug profit in the global market for many years, only the United States market returns number of over $1 billion a year. And the innovation of the Chinese medicine has just listed will soon face a big price cuts, is not reasonable. In the case of curative effect is consistent, domestic high-quality generics more cost-effective."
Health care medicine market will increase rules and generate new opportunities. Such as domestic path for, compaq heap and imported large varieties, such as by bead sheet resistance, rituxan, etc are not to enter the new catalogue of the health care consists of "the xxix olympiad", but considering the clinical demand, around the involved in the health care or a serious illness insurance is another option.
Hundred hui precision medical holding group co., LTD., vice President of Tian Gulun told reporters: "enterprise must do trade-off between price and the market." Patent medicine on the business model, he thought, there are three kinds of strategies: one is the continuation of the high price system, do the high-end market, the difference between a high-volume, low-margin business competition in the domestic logic; 2 it is to implement charity aid projects, for patients based on the premise of high prices, charity, to buy a gift for circulation pattern; 3 it is active in market prices. At present some brands by slashing prices into the directory, and then cancel give medicine, patients did not actually benefit from it. Health talks, the biggest impact should be drug patents expire.
Right now, medicare drug payment standards in advance according to the common name of work imminent. "Hospitals purchasing desire will be reduced." Tian Gulun, according to the structural medical institutions reduce the drug dosage, the free market will translate into high quality generic drugs and the innovation medicine market, but with molecules of the original drugs and generic drugs in chemical name take the lowest price paid, the premise is the product quality in line with curative effect.
|
